Innovent Biologics Inc

📅 Upcoming

🕒 Recent(90d)

News

• Lilly’s latest China drug deal; Immunovant’s setback in lupus
  Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded a…
  biopharma_dive · 9d ago
• China poses increasing security risk as US biotech innovation edge erodes
  The U.S. is scrambling to compete with a strategically positioned China on the biotech stage as the Asian country surpasses America in biomedical research and clinical trials. So far, China is winn…
  biospace · 1mo ago
• RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
  Plus news about Avere Therapeutics, Novo Nordisk, Sobi, Innate Pharma, Oculis, Innovent Biologics and Daiichi Sankyo. 🌏 BeOne gets rights to RevMed drugs in 'select Asian markets': The deal includ…
  endpoints · 1mo ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 2mo ago
• J&J dips despite upbeat outlook; AstraZeneca, Spero cut China deals
  J&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.
  biopharma_dive · 2mo ago
• In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic
  After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet. An autoimmune drug candidate from th…
  endpoints · 2mo ago
• These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.
  Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.
  biopharma_dive · 3mo ago
• At BIO, tension over China biotech deal regulation looms
  Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic entrepreneurs’ ambitions in the sector.
  biopharma_dive · 3mo ago
• Innovent declares Phase 3 success for ADC that attracted huge Takeda deal
  Innovent Biologics' ADC candidate has passed a Phase 3 trial in advanced stomach cancer and is under priority review in China, but details of the success are still under wraps. The Phase 3 win will…
  endpoints · 4mo ago
• Otsuka showcases kidney drug data; Pfizer cuts an AI deal
  Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
  biopharma_dive · 4mo ago